文摘
摘要目的:评估123 i-fp-cit SPECT区别与路易体痴呆(下文)阿尔茨海默病痴呆(ADem)和多通道成像是否提供额外的价值。
背景:减少striatonigral吸收123 i-fp-cit SPECT反映出多巴胺功能障碍,而其他成像标记一起使用时,可以互补。
设计/方法:Ioflupane-SPECT、核磁共振摄影,PiB-PET评估35路易体痴呆14亚当的病人(包括12个患者最终解剖)。Striatonigral多巴胺转运体吸收是评估方法与123年i-fp-cit SPECT使用DaTQUANT软件(通用电气医疗集团)来计算壳核吸收的z得分。与结构的MRI海马体积计算,扣带岛与正签订(CIS)的比率,和全球皮质与PiB-PET加以保留。
结果:低DaTQUANT z得分下文的壳核观察患者相比ADem病人(c-statistic 0.916, p < 0.001)。的DaTQUANT壳的z分数显示在区分下文c-statistic ADem高于在MRI海马体积(c-statistic 0.739, p = 0.016),独联体在摄影(c-statistic 0.878, p = 0.002),或全球PiB-PET皮质加以保留(c-statistic 0.884, p = 0.001),尽管有些重叠两个诊断小组还观察到与单一成像方法。添加另一个成像形态123 i-fp-cit SPECT增强c-statistics同样与每个组合(+ MRI 0.968, +正0.975,+ 0.975 PiB-PET),和123年i-fp-cit SPECT结合MRI和PiB-PET显示最高的0.996 c-statistic当三个成像模式的总和。
结论:Ioflupane-SPECT是个优秀的成像模式识别下文通过检测striatonigral多巴胺功能障碍和潜在Lewy-related病理学。相关神经成像和核磁共振、摄影或PiB-PET可能增加增量价值差异化路易体痴呆ADem和检测并发广告和Lewy-related病态。
披露:Miyagawa博士没有披露。斯科特Przybelski没有披露。丹妮拉Maltais没有披露。Hoon-Ki分钟没有披露。列侬乔丹没有披露。盖Lesnick已收到个人赔偿作为梅奥诊所的一名雇员。Graff-Radford博士已经收到个人赔偿作为梅奥诊所的一名雇员。Graff-Radford博士已经收到个人薪酬在5000 - 9999美元的范围作为一个编辑,副主编,或为美国神经病学学会编辑顾问委员会成员。首页Graff-Radford博士的机构收到NIH的研究支持。琼斯博士没有披露。 The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc. Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc.. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Walter Kremers has nothing to disclose. Ms. Forsberg has nothing to disclose. Ms. Allen has nothing to disclose. Joseph E. Parisi, MD has nothing to disclose. The institution of Ross Reichard has received research support from NIH. An immediate family member of Ross Reichard has received publishing royalties from a publication relating to health care. Melissa Murray, PhD has nothing to disclose. Dr. Dickson has nothing to disclose. Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Biogen. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Alector. Dr. Boeve has received publishing royalties from a publication relating to health care. The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
